CancerDrs

Lung Cancer clinical trials in Ohio

58 actively recruiting lung cancer trials at 41 sites across Ohio.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Ohio:
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Aultman Health Foundation — Canton, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Ohio:
  • Aultman Health Foundation — Canton, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
  • Miami Valley Hospital — Dayton, Ohio
  • Miami Valley Hospital North — Dayton, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Ohio:
  • UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
  • Case Western Reserve University — Cleveland, Ohio
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Ohio:
  • Local Institution - 007-893-B — Cincinnati, Ohio
  • USOR - Oncology Hematology Care - Blue Ash — Cincinnati, Ohio
  • Local Institution - 007-893-C — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
  • Mark H. Zangmeister Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Ohio:
  • Aultman Hospital — Canton, Ohio
  • Aultman Medical Group Hematology and Oncology — Canton, Ohio
  • Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
  • Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
  • Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Ohio:
  • Research Site — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…

Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Ohio:
  • University Hospitals Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
  • Gabrail Cancer Center Research — Canton, Ohio
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
  • University Hospitals Seidman Cancer Center at UH Mentor Health Center — Mentor, Ohio
  • UH Minoff Health Center at Chagrin Highlands — Orange, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Ohio:
  • Summa Health ( Site 4011) — Akron, Ohio
  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0028) — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center ( Site 0023) — Cleveland, Ohio
  • OSU Brain and Spine Hospital ( Site 0016) — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Ohio:
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Ohio:
  • Local Institution - 0369 — Canton, Ohio
  • Local Institution - 0486 — Centerville, Ohio
  • University of Cincinnati Medical Center — Cincinnati, Ohio
  • Local Institution - 0199 — Cleveland, Ohio
  • Local Institution - 0366 — Massillon, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in Ohio:
  • Oncology Hematology Care, Inc — Cincinnati, Ohio
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Ohio:
  • Local Institution - 0163 — Cleveland, Ohio
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Ohio:
  • University of Cincinnati — Cincinnati, Ohio
  • Case Western (University Hospitals Case Medical Center) — Cleveland, Ohio
  • Cleveland Clinic — Cleveland, Ohio
  • Ohio State University Wexner Medical Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Ohio:
  • Gabrail Cancer Center Research — Canton, Ohio
  • The Christ Hospital Cancer Center — Cincinnati, Ohio
  • University of Cincinnati Medical Center — Cincinnati, Ohio
  • The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion — Cleveland, Ohio
  • Cleveland Clinic — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Ohio:
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…

Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Ohio:
  • University Hospitals Seidman Cancer Center — Sandusky, Ohio
  • Taylor Cancer Research Foundation — Toledo, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Ohio:
  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103) — Cincinnati, Ohio
  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106) — Kettering, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in Ohio:
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Saint Elizabeth Boardman Hospital — Boardman, Ohio
  • Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
  • Oncology Hematology Care Inc-Kenwood — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Ohio:
  • Aultman Health Foundation — Canton, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
  • Miami Valley Hospital — Dayton, Ohio
  • Premier Blood and Cancer Center — Dayton, Ohio
  • Miami Valley Hospital North — Dayton, Ohio
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio:
  • The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Ohio:
  • Cleveland Clinic — Cleveland, Ohio
  • The Ohio State University, Department of Psychiatry — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Ohio:
  • Cleveland Clinic — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Ohio:
  • Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
  • University Hospital - Cleveland Medical Center — Cleveland, Ohio
  • Cleveland Clinic — Cleveland, Ohio
  • Zangmeister Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Ohio:
  • Cleveland Clinic — Cleveland, Ohio
View on ClinicalTrials.gov →

Showing 25 of 58 trials with sites in Ohio. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07